Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingPhase 22026-04-22NCT05972135

2 results · Page 1 of 1

Swipe the table sideways for more columns.

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Arizona Oncology AssociatesTucsonUnited States5
Blue Ridge Cancer CenterRoanokeUnited States1
Colorado Blood Cancer InstituteDenverUnited States178
Florida Cancer SpecialistsLake MaryUnited States6
Maryland Oncology HematologyColumbiaUnited States6
Medical Oncology Hematology ConsultantsNewarkUnited States9
Minnesota Oncology HematologyMinneapolisUnited States5
Oncology Associates of OregonEugeneUnited States12
Oncology Hematology CareCincinnatiUnited States13
Rocky Mountain Cancer CenterDenverUnited States13
Texas OncologyAustinUnited States6
Texas Oncology - Northeast TexasTylerUnited States18
Texas Oncology - San AntonioSan AntonioUnited States12
TriStar Bone Marrow TransplantNashvilleUnited States8
Vanderbilt- Ingram Cancer CenterNashvilleUnited States2
Virginia Cancer SpecialistsFairfaxUnited States109
Virginia Oncology AssociatesElizabeth CityUnited States1